Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GDP out of Germany was better than expected.
Futures and Euroland like.
true.
Gotta look at the technicals for indication of where buy/sell limits might be placed fwiw
15.88----->16.88---->17.50---->27.00 technical levels.
Sorta like the same pull back we saw when it hit 13.50 (which was the same level as a very technical 13.50 level back in 2003).
15.88 was a point going back ten years -
Sectoral Asset Management
8.9 million share over 5% position
(these are good healthcare funds)
I think Blackrock's ownership is a combination of Blackrock's previous ownership as well as Barclay's previous ownership (whom they acquired).
Royal Banc of Canada (RBC Dominion)
RBC initiated today with 20 price tgt
LOL.
just busting chops, thats all.
I didnt see this move coming at all.
Isn't there already a lot already priced into the shares at the ~$1B market cap
Blackrock
Owns 11+ million per SEC filing
Did I say I dislike sell side analysts?
I was under the impression that CDX-011 was THE reason to be involved here. Am I mistaken?
More like the email went to the Outlook "BULK MAIL" folder instead of the "INBOX".
LOL, sad...but plausible.
support is trending on the 20 EMA.
then comes the 50 EMA a little below 14.
New Institutional Shareholder
BB BIOTECH AG
12/31/2011
3,250,448 shs
New
Out of Zurich, I believe.
Maybe Scangos can just buy his old company now with Biogen money ...and the healthcare media/peers can proclaim him a genius again. He can use Biogens assets to further develop the 10 or so other me-too drugs he spent several hundreds of millions developing that are now a dust bin collection.
...i say this in jest.
Cabo certainly is a real drug - I just think EXELs management is pretty weak and screwed up dose escalation first off, and now probably don't have a clear idea of what they even want to do with Cabo. I can honestly see these guys spending a hundred or so million on further development of the drug and then realizing they designed the trial incorrectly.
LOL - today's low was literally brought down to fill the gap from Friday a.m.
OT...CLASSIC
“We’re a believer; we’re celebrating. We think the rally has legs,” explains Gina Sanchez, Roubini’s director of equity and allocation strategy.
115 enrolled to date
Yeah, it could go to 10, but has absolutely NOTHING to do with your awfully flawed reasoning behind it.
Kirkman has said they wouldn't do a fund raise until after the second interim. I am actually surprised (i do not know if positvely or negatively surprised) that they are doing this through an ATM. I normally hate these types of transactions. my first thought is they probably would have liked to have done an underwritten financing with the S-1 they filed a month ago, except it probably wasn't very well received prior to such a binary event. With the ATM, Cowen (reputable, not a bucket shop) can now take advantage of any type of exhuberant frenzy which might occur due to some bogus rumor before the actual readout.
FWIW, Merck KGaa shares continue to trend very strong going into this event - hopefully the Germans have leaked :)
I think that if you are asking this question now, it is very frightening because it means things are getting frothy ( unfortunately)
Yes, this is old (as you just mentioned). It's been on their site for a few months now. Not really sure why it's all of a sudden "out there" in youtube and twitterland just recently.
This deal really did seem to come out of nowhere. No volume in recent days leading anyone to think something like this would happen.
It's one thing that surprises me about the biotech industry---management and people in these deals seem to really keep these things under tight wrap. Seen many instances in other sectors where you know something is going on, because of vol and price action.
This looks like a horrific deal.
But wait...is Al Mann, himself, through his LLP or whatever it is, the sole investor? Or is he buying an ADDITIONAL 32 million shares at the offering price? I dont even really want to look at it any more than simply heading it really quckly, because I never really have had an interest in the company. FDA has a hard on for these types of drug devices..
LOL
Bear raid. I *HOPE* I am never witness to one of them in my positions.
The only TRUE "raid" I saw was in DNDN, when I went to the bathroom and it was trading at 18, and within 5 minutes, it went to 8, and back to 18 (from what I can remember). I miss a huge opportunity for an amazing trade all in the time it took for me to hit the urinal.
Taltorvic = Ridaforolimus Brand name
FDA Panel--March 20
If I was a big corporation with big cash flow, I would be doing the same thing. Hell, I would be trying to float 100 year bonds if I could.
If I had to guess, I would say the same seller in aria is the same seller in pcyc. they're trading similarly. both both very strong charts still.
Must have a been a "bull raid" :o)
...end of month ETF/portfolio rebalances.
end of month rebalance....
Does someone want to do the honors and embarrass themselves by calling this a "bear raid"?
Adam F., on Twitter:
“@adamfeuerstein: New drug names: The good -- Roche's Erivedge -- & the bad -- $LLY's Jentadueto. The latter sounds like something I'd get at $SBUX w/ no foam”
I agree. These mid day approvals suck. They cause too much panic.
Would have rather seen a gap in the a.m., that would prob have been filled anyway due to momentum guys selling the news.
"percent of ownership etc. -- is such a big secret"
Probably because it is either so small, or, at the time, Bellicum was a complete nobody and it wasn't even worth mentioning.
Perhaps some analyst should ask Berger that at the next conference. Oh. Wait. The sellside guys don't even know what Bellicum is....nevermind.
I think buying Bellicum, with an already bloated share count, would be a REALLY poor decision. I dont think there is even a slight chance of this happening. Further, there is no way Ariad could afford it with their cash, nor is there even a remote chance of them doing it with a debt deal (zero chance).
If Bellicum IPO'd, and Ariad actually owns any amount (worth talking about), it is a hidden asset that not a SINGLE analyst I know of, even speaks about, or let alone, knows exists. In fact, I wonder how many real investors even know what AP1903 is or Bellicum.